{"name":"Nivalis Therapeutics, Inc.","slug":"nivalis-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxPeTBMZUIwaV9wcWV3WkQ0N09FbFRIdkoxS0NUS3VRMS1fRmlub0xWekJzeXFhLTFnQUg1b3pjZXUyT25vT296NnJvYV9xVE0tQ3JvQ09sSGFjUmgxc3lLNnh0Y1kzc0lsR0xDRTBNLUhwS0RyM3dYdHRVYjdlZG9XVkZVcDJEV3pjb18yYmE3bFdZalVSQ2lPMGRtMDdPamd1b1NvYXdvLW9kQmF1SnhGY2hHRU04NnFVbS1GT1ZPWmV5NnZvTW1rSy04OWpRdWVwSmpmakdndlFRQkEzaHVBOUhfdm1CYjBwTkphWkd2ZkZIcWJtUGdMREEzM0d3d1ByQUY0cFBrYVZSZw?oc=5","date":"2026-04-06","type":"pipeline","source":"The Globe and Mail","summary":"Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors - The Globe and Mail","headline":"Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOTERLN3dVSHhKeHQyZzROWHVlZkpTZDgwWll1emFjY1dBYnhPTk5TTkNVWHVLN1JLdFpPT29xaHFFNDJwMF9oN2V2VkdNR1FKc3h1aHNjSEVxN3NOaHNJWGlQZTdiU3VnUHZMcHozb2wzREdqWXE4ekFjcXVfeFA0cC1lajAtVTVmaFBqRmFCT3V4VWhYMXp3SGJmUjRJSWpfREk5Yng2TUxEbW1USXlQSTdsTlNlVF9kZ2NtNGNOOW5MdWU1SzF5M1BURFVwOWR6OGlXUW94eTFmYjZOVGt6d2ZQeDhxYktVRUJBUklEZ1BRVnk4alpuMnBPYTY1Zw?oc=5","date":"2026-03-31","type":"pipeline","source":"Sahm","summary":"Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - Sahm","headline":"Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQN1V4UGgtNTNNU1JDQ0xzc3A0MkVFbk0xWWY5aXBtNDhMX1pIX3FIaTJHejJ5U2ROUjF4TWZaMHlwNkZCVDRYZi12cFZBSEMwblNwWnk3WnNiU21rNEFqU1pxSUdQVFkteFZDZmt1WE8zeEZDN3hrSkdaVmpCSV9vYl93Nlc?oc=5","date":"2026-03-31","type":"pipeline","source":"citybiz","summary":"Immunic Appoints Jon Congleton To Board - citybiz","headline":"Immunic Appoints Jon Congleton To Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQdzJpalFmZ3B2XzdlMm9FR0RwbUowZEQyb2RlNUFuMEc4WWJ1WGtJb0c2Yzk5RTVfenZTU3hMeHdwaEZKU1lGdEVqR2w1cnhMY05GX3pOTlVxbUxOYnJGVmVZTWctWHR5OHRkejFPOElHRDJPQWVfQXlYWkRkcVZjcmNJa1Y4dDBHNTRlNkdPQjF3Q3MtSmtUSWJwaV9wUDRWZjJRU0NR?oc=5","date":"2024-04-08","type":"pipeline","source":"The Business Journals","summary":"Alpine Immune Sciences promotes T-Mobile vet in finance role - The Business Journals","headline":"Alpine Immune Sciences promotes T-Mobile vet in finance role","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNaGxxNkRKTG9uYmF2Rzg5MTRRVmI4d3prU2pCYmtsWXU1SDBMSkFXdE1FZWhpeFBDNjc4ZjFoM2JXYlpZVHZKb1pBZGdPODREVzZxMHJmX2I0MDR4cHFMV3NrQWwtLXoyUmM3cWdSckJkWHBDWldUaTMydW1RQmJfeFpkUE80d3FwaWgyYmx5VUZ4ZHJwNjB3RGZVcFRPOGo3dkRZZkhta0phTEJmNnVXQzZnbTd6N193cXRtUWRibw?oc=5","date":"2018-07-19","type":"trial","source":"Clinical Leader","summary":"A Cost-Utility Analysis Of Vertex's CF Drugs — What It Teaches Us About Trial Design - Clinical Leader","headline":"A Cost-Utility Analysis Of Vertex's CF Drugs — What It Teaches Us About Trial Design","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNZlF2T0t3RFhoaFR1VVNuMnloZi1tcno4V1ZCY2hxVzN5d1p1Z2t5eWdObkNSMDZaY003ZnoxaW9STUdSTlZCQWk5eGJqdy1nQTVlNHdzc1d0WHNPUjBRZUNNMVA5YS12QUZVTWdfcVMyNEphbG92Z0UzSmpTMUI2c212UTktcnNfSlNfSllVWVFXZ0JHQ05Nd191UkM5Nld5RC04Qy1zN3ZNVDF5ZF9qdHBXQ0FsWjQ1NEVHY2lObWRzUzlaNF9v?oc=5","date":"2017-04-19","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Failed CF Drug Firm Nivalis to Merge with Immunotherapeutics Specialist Alpine - Genetic Engineering and Biotechnology News","headline":"Failed CF Drug Firm Nivalis to Merge with Immunotherapeutics Specialist Alpine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQQVdUWldwd2RNRlNkMmlEMXNfbW5pM3U2QklaRUhYMTJ6U3dGeHlzcWtlallkV3lNX0U3eUpEa2lqNkRpcTdxOG9ScjE3Qnk2TXRFRDN4Z0xSb2FESk1HM3NmSXRtZGtWa1ozOU9VemtranBJS0lPcWR4dW8tbmxRTDJlMmFkSjZGa1E?oc=5","date":"2017-04-19","type":"deal","source":"BioPharma Dive","summary":"Former Dendreon CEO debuts new public company in reverse merger - BioPharma Dive","headline":"Former Dendreon CEO debuts new public company in reverse merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNaF8wOTdkVFpwS3VHMlRsMlprUkZyRUNUSGZrM3RzME5pRU5EZ1FxVzhKbjdkbTFtdGNuZDhtbW9ETml4Q2ZpTDYzRGZTS1UtZVdmd1poenpqdVRiMW9oVU9xX0NQVUNIbFRJWGI5WmVqd1BPdm9fTHMzbHFHTWdLT1BOZ1ZSYTdxS3d2R1RqT2ZVbGt6?oc=5","date":"2015-03-09","type":"pipeline","source":"Cystic Fibrosis News Today","summary":"CF Drug Developer N30 Pharmaceuticals Is Now Nivalis Therapeutics - Cystic Fibrosis News Today","headline":"CF Drug Developer N30 Pharmaceuticals Is Now Nivalis Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}